Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of LP lesions, hypertrophic LP (HLP) lesions, and healthy controls

ABSTRACT: Transcriptomic profiling of LP lesions, hypertrophic LP (HLP) lesions, and healthy controls

PROVIDER: PRJNA540067 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic profiling of LP lesions, hypertrophic LP (HLP) lesions, and healthy controls

Project description:The microarray experiment was employed to evaluate the gene expressions in skin lesions of LP, hypertrophic LP (HLP), and healthy controls.

2020-01-01 | GSE130403 | GEO

Gene expression profile of epidermis from psoriasis lesions and healthy controls

Project description:Gene expression profile of epidermis from psoriasis lesions and healthy controls

| PRJNA700654 | ENA

Gene expression profile of epidermis from psoriasis lesions and healthy controls

Project description:Psoriasis is characterized by hyperplasia and disrupted differentiation of keratinocytes. Keratinocytes are considered not only the target but also the critical participants. To explore the role of keratinocytes in psoriasis, we used microarrays to compared gene expression profile of epidermis between psoriasis lesions and healthy normal skin.

2021-02-09 | GSE166388 | GEO

Transcriptomic profiling of dermatomyositis lesions.

Project description:The microarray experiment was employed to evaluate the gene expressions in skin lesions of dermatomyositis and healthy controls.

2020-04-06 | GSE142807 | GEO

Gene expression profiling of chondrodysplasia mutants and isogenic controls during hypertrophic induction from iPSCs

Project description:In order to better understand chondrodysplasia disease mechanisms, we induced hypertrophic chondrocytes from chondrodysplasia-specific iPSCs and analyzed their gene expression profile. This dataset includes the expression data obtained from iPSC-derived cartilage pellets on day 56 of hypertrophic induction. Three COL10A1 mutants and two MATN3 mutants were compared to their isogenic controls to determine the effects of each mutation on the unfolded protein response.

2020-05-20 | GSE148728 | GEO

Differential Expression of MicroRNAs in Leprosy Skin Lesions

Project description:In this study, a comprehensive assessment of human miRNA was performed on leprosy skin lesions using DNA chip microarrays, which included the entire spectrum of the disease along with its reactional states. Sixty-eight samples from leprotic lesions (10TT, 10BT, 10BB, 10BL, 4LL, 14R1, and 10R2) and nine skin biopsies from healthy individuals were used as controls (CC) (ages ranged from 06 to 83 years, 48 were male and 29 female). The evaluation identified differentially expressed miRNAs [Fold Change (FC)≥2.0, p<0.05] in disease lesions versus healthy controls or between them. Some of these miRNAs were validated by RT-PCR.

2017-10-31 | GSE102314 | GEO

miRNA expression profiles in the serum of cats with hypertrophic cardiomyopathy compared to healthy cats

Project description:MicroRNAs negatively regulate gene expression and may serve as biomarkers for human cardiomyopathy. In the domestic cat, hypertrophic cardiomyopathy (HCM) represents the most common primary cardiomyopathy. In humans, the etiology of HCM is linked to mutations in genes of contractile muscle proteins, while in cats a clear proof for causal mutations is missing. The etiology of feline HCM is uncertain. Diagnosis is made by heart ultrasound examination and measuring the serum level of N-terminal pro B-type natriuretic peptide. The purpose of this study was to investigate whether microRNA profiles in the serum of cats with HCM are different from the profiles of healthy cats and whether specific miRNAs can be detected to serve as potential biomarkers for feline HCM or may help in understanding the etiology of this disease Blood was drawn from two groups of cats: 12 healthy cats and 11 cats suffering from hypertrophic cardiomyopathy. After clotting, samples were centrifuged and total mRNA was extracted from serum. These 23 serum samples were analyzed and the groups were compared

2015-07-22 | E-GEOD-49427 | biostudies-arrayexpress

Darapladib, an inhibitor of Lp-PLA2, sensitises cancer cells to ferroptosis by remodelling lipid metabolism

Project description:Arachidonic and adrenic acids in the membrane play key roles in ferroptosis, but how these fatty acids are manipulated in cells is largely unknown. Here, we reveal that lipoprotein-associated phospholipase A2 (Lp-PLA2) controls intracellular phospholipid metabolism and contributes to ferroptosis resistance. A metabolic drug screen revealed that darapladib, an inhibitor of Lp-PLA2, synergistically induced ferroptosis in the presence of GPX4 inhibitors. Notably, darapladib was able to enhance ferroptosis under lipoprotein-deficient or serum-free conditions. Furthermore, Lp-PLA2 was located in the membrane and cytoplasm and suppressed ferroptosis, suggesting the critical role of intracellular Lp-PLA2. Lipidomic analysis showed that darapladib treatment or deletion of PLA2G7, which encodes Lp-PLA2, generally enriched phosphatidylethanolamine (PE) species and reduced lysophosphatidylethanolamine (lysoPE) species. Moreover, combination treatment with darapladib and PACMA31, a GPX4 inhibitor, efficiently inhibited tumour growth in a xenograft model. Our study suggests that inhibition of Lp-PLA2 is a potential therapeutic strategy to enhance ferroptosis in cancer treatment.

2023-10-24 | PXD044002 | Pride

Human Hypertrophic Cardiomyopathy mRNA Profiling.

Project description:Cardiac biopsies were obtained from hypertrophic cardiomyopathy (HCM) patients and controls and subjected to mRNA profiling.

2024-11-12 | GSE249925 | GEO

Proteomic dataset on abnormal glucose tolerance versus healthy controls with 10 abnormal glucose tolerance. 10 in healthy controls

Project description:Proteomic dataset on abnormal glucose tolerance versus healthy controls with 10 abnormal glucose tolerance. 10 in healthy controls

2023-09-18 | PXD045432 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data